Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Open Innovation for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Due Diligence
Comparison
 
Due Diligence
Overview
Top Applications
Online Panel Discussions
Request Consultation
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
Forums
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Hyalomatrix® PA

Hyaluronan based matrix to manage severe burns and full-thickness wounds

Mechanism of action

Hyalomatrix® PA is a bioresorbable dermal substitute made of HYAFF®, a derivative of hyaluronan providing a microenvironment suitable for optimal tissue repair and accelerated wound healing

Full description

Hyalomatrix® PA is the most recent product developed in wound care line of FAB, which is based on the exclusive, innovative and proprietary hyaluronan biopolymer technology. Hyalomatrix® PA is a three-dimensional, non woven HYAFF® matrix layered on a transparent silicone membrane specifically intended for the treatment of deep burns and full-thickness wounds. Hyalomatrix® PA also provides an excellent wound preparation to support the implantation of autologous skin grafts.

Development status

Registered

Patent information

HYAFF® and its use are patent protected. The product is CE marked and 510(k) approved by US FDA.

Type of business relationship sought

Hyalomatrix® PA has been licensed for distribution and sale in Argentina, Cyprus, Egypt, France, Greece, Iran, Israel, Italy, Rep. of Korea, Mexico, Saudi Arabia and UAE.

It is available for distribution in all other countries world wide.

Licensing contact

Mr Alessandro Di Martino
Head Manager
International Markets
Request more information

More information

For more information about the product please visit website.

Company details

FAB-Fidia Advanced Biopolymers
The core technology of FAB is based on a new class of patented biopolymers obtained from chemical modifications of hyaluronan

Related reports

Are you looking for reports related to this particular subject. Our Reports section is the best place to start.

Related items

Related categories

Research Partnership for Due Diligence Execution
Genesis
Pharmaceutical Antitrust
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us